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BCPareconsideredthemostpromisingbiomaterialsforbonereconstruction.Thisstudyaimsatanalyzingtheoutcomesofpatients
who received BCP as bone substitutes in orthopaedic surgeries. Sixty-six patients were categorized according to the etiology and
morphology of the bone defects and received scores after clinical and radiographic evaluations. The ﬁnal results corresponded to
the combination of both parameters and varied from 5 (excellent result) to 2 or lower (poor result). Most of the patients who
presented cavitary defects or bone losses due to prosthesis placement or revision, osteotomies, or arthrodesis showed good results,
and some of them excellent results. However, patients with segmental defects equal or larger than 3cm in length were classiﬁed as
moderate results. This study established clinical parameters where the BCP alone can successfully support the osteogenic process
and where the association with other tissue engineering strategies may be considered.
1.Background
Commercial bioactive ceramics used for bone repair include
calcium carbonate (CaCO3, in aragonite form), calcium
sulfate (CaSO4·2H2O, plaster of Paris), calcium phosphates,
and bioactive glasses. Calcium phosphate ceramics include
beta-tricalcium phosphate [β-TCP, Ca3(PO4)2], hydroxyap-
atite [HA, Ca10(PO4)6(OH)2], and biphasic calcium phos-
phate (BCP) (consisting of an intimate mixture of HA and
β-TCP of varying HA/β-TCP ratios).
Unknowingly, the ﬁrst preclinical application of BCP was
reported by Nery et al. in 1975 using a calcium phosphate
they described as “tricalcium phosphate” but was analyzed
using X-ray diﬀraction as a mixture of HA and β-TCP [1]
and,consequently,suchamixturewasdescribedasabiphasic
calcium phosphate, BCP [2, 3]. The elaboration of BCP
was ﬁrst introduced by LeGeros in 1986 [4]. The eﬃcacy of
BCP was based on the preferential dissolution of the β-TCP
compared to HA, allowing the manipulation of bioactivity
or biodegradation by manipulating the HA/β-TCP ratio [5].
Concentrated studies on their development and applications
were made by Daculsi et al. [6–8].
Thus, through the combination of a balanced rate
between a more stable phase (HA) and a more soluble one
(β-TCP),itwaspossibletoformulateaBCPwithacontrolled
dissolution rate and diﬀerent mechanical properties [5].
The presence of porosity and a bioactive surface facilitate
cell attachment, proliferation, and diﬀerentiation and, con-
sequently, provide a more biocompatible, osteoconductive,
and in some cases, osteoinductive ceramics, which can favor
increasedboneformation[6,7,9–20].Indeedthesechemical
and physical properties, produced by variations of the
temperature, pH and duration of the sintering process, make
eachbiomaterialuniqueandleadtodiﬀerenttissueresponses
[7, 10, 12, 13, 16–18]. Currently the BCP represents the most
promising and best alternative for bone reconstructions as
they can overcome the shortcomings of the autografts and
allografts such as expense, limited supply, additional trauma2 International Journal of Biomaterials
in the case of autografts, and risk of disease transmission in
the case of allografts.
The objective of this study is to provide a retrospective
evaluation,throughtheanalysisofrandomly selectedclinical
cases, of the long-term eﬃcacy and performance of BCP
bioceramics as bone substitutes for the reconstruction of
defects with diﬀerent morphologies and caused by distinct
etiologies.
2. Methods
2.1. Biphasic Calcium Phosphate (BCP) Bioceramics. The
BCP bioceramics (Osteosynt, EINCO Biomaterial Ltda.,
Belo Horizonte, Minas Gerais, Brazil) used for the recon-
struction of the defects in 66 patients is composed of 65%
of HA and 35% of β-TCP, with a tolerance of ±5%, and
characterized by the presence of intercommunicating micro-
and macroporosity of <10μma n d>100μm, respectively.
The two diﬀerent forms used were the granular form
(20–40mesh and 40–60mesh) and a prefabricated wedge.
The characterization of the crystalline phases of the BCP
was performed using X-ray diﬀraction (XRD) (Phillips-
PANalytical PW1710, USA); the presence and sizes of porous
were demonstrated by scanning electron microscopy (SEM)
(S-3500N, Hitachi).
2.2. Clinical Cases. This study was approved by the Ethics
Committees of the Hospital S˜ ao Bento Cardioclinica S.A.
(Belo Horizonte, Minas Gerais, Brazil) and all the subjects
participating in the study signed a consent form.
T h i ss t u d yi sar e t r o s p e c t i v ee v a l u a t i o no f6 6r a n -
domly chosen clinical cases of patients who had undergone
orthopaedic surgeries with BCP as bone graft substitute.
These sixty-six patients corresponded to 67 surgical
procedures (one patient had bilateral interventions). Thirty
seven patients were males and 29 females. One patient was
1-year old and one, 70-year old. The ages of the other 64
patientsrangedbetween15-yearand69-yearoldwithamean
age corresponding to 41.6 years (Table 1).
Thedefectswereclassiﬁedaccordingtotheetiologyofthe
lesions and the morphology of the bone defect. Regarding
the etiology, the defects were divided into the following:
(1) orthopaedics defects (32 patients and 33 defects that
corresponded to 33 surgical procedures), comprised of
bone defects resulting from elective surgical procedures,
such as total hip prosthesis (placement and replacement),
osteotomies, and arthrodesis and (2) traumatic defects
(34 defects corresponding to 34 surgical procedures),
which included noninfected pseudoarthrosis, fractures, and
arthrodesis after posttraumatic arthrosis.
Regardingthemorphology,thedefectsweredividedinto:
(1) cavitary bone defects (42 defects) and (2) segmental
bone defects (or gap defects) (25 defects). The volume of
the cavitary bone defects were not measured due to the
irregularityoftheirshape.Thesizeofsegmentalbonedefects
was measured from the X-Ray images, and their largest
length was noted.
Table 1: Description of age, gender, and aﬀected bone of each
patient. The initial diagnosis is described in parenthesis. F: female;
M: male.
Procedure ID Age Gender Bone
01 25 F Femur (pseudarthrosis)
02 50 M Hip prosthesis (revision)
03 51 F Femur (pseudarthrosis)
04 32 M Knee (osteoarthrosis)
05 51 F Tarsus (osteoarthrosis)
06 69 F Ankle (pseudarthrosis)
07 53 M Hip prosthesis (revision)
08 64 F Hip prosthesis (revision)
09 33 M Tibia (fracture)
10 49 M Femur (osteonecrosis)
11 46 M Calcaneus (fracture)
12 20 M Femur (osteonecrosis)
13 53 M Femur (pseudarthrosis)
14 34 M Radius (pseudarthrosis)
15 46 M Femur (osteonecrosis)
16 37 M Ankle (fracture)
17 38 F Tibia (pseudarthrosis)
18 41 F Radius (fracture)
19 38 F Acetabulum (reconstruction)
20 16 F Tibia vara
21 35 F Calcaneus (fracture)
22 43 F Clavicle (pseudarthrosis)
23 28 M Carpal bone (arthrosis)
24 42 M Hip prosthesis (revision)
25 58 M Hip prosthesis (revision)
26 27 M Femur (pseudarthrosis)
27 01 M Clavicle (congenital pseudarthrosis)
28 65 F Hip prosthesis (revision)
29 50 M Hip prosthesis (revision)
30 60 F Hip osteoarthrosis
31 36 M Humerus (fracture)
32 70 M Wrist (osteoarthrosis)
33 24 M Radius (fracture)
34 33 M Calcaneus (fracture)
35 32 M Forearm (pseudoarthrosis)
36 28 M Forearm (pseudarthrosis)
37 46 F Femur (pseudoarthrosis)
38 56 M Ankle (fracture)
39 41 F Knee (osteoarthrosis)
40 44 F Femur (osteotomy)
41 33 M Femur (fracture)
42 49 F Ankle (fracture)
43 22 F Femur (pseudoarthrosis)
44 34 F Calcaneus (fracture)
45 01 M Clavicle (congenital pseudarthrosis)
46 60 F Humerus (pseudarthrosis)
47 30 M Tibia (pseudarthrosis)
48 59 M Tibia (pseudarthrosis)International Journal of Biomaterials 3
Table 1: Continued.
Procedure ID Age Gender Bone
49 56 M Radius (fracture)
50 23 F Humerus (fracture)
51 30 M Humerus (pseudarthrosis)
52 34 F Ankle (arthrosis)
53 57 F Elbow (osteoarthrosis)
54 33 M Femur (fracture)
55 59 F Humerus (pseudarthrosis)
56 40 M Femur (osteonecrosis)
57 15 F Femur (genu valgum)
58 37 M Tibia (fracture)
59 64 F Hip prosthesis (revision)
60 63 M Tibia (fracture)
61 21 F Femur (genu valgum)
62 19 M Femur (pseudoarthrosis)
63 46 M Femur (pseudoarthrosis)
64 38 M Knee (osteoarthrosis)
65 50 F Hip prosthesis (revision)
66 62 F Hip prosthesis (revision)
67 38 M Ankle (pseudoarthrosis)
2.3. Surgical Procedures. The surgical technique used for the
implantation of BCP followed the surgical principles that
are equivalent to those required for autografts: curettage
and debridation of the wound site until viable bone tissue
could be observed and impaction of the bioceramics. The
bioceramics was applied directly into the bone defects and
no extra volume of the bioceramics was used except for
the arthrodesis procedures where the creation of an external
bridge between the bone extremities was necessary. External
or internal ﬁxation systems (AO/ASIF methods) were used
according to the indications for each patient.
In acute traumatic lesions, open reductions were per-
formed, and the defects were immediately ﬁlled with the
BCP.
Three patients received a combination of autografts and
BCP: one presented a pseudoarthrosis of the femur with a
gap bone loss of 11cm in length, one had a bimalleolar
fracture of the ankle (considered a cavitary bone defect), and
the other presented a pseudoarthrosis of the tibia, with a
bone gap of 4cm in length.
2.4. Clinical and Radiographic Evaluation. The classiﬁcation
of the ﬁnal results was based on clinical and radiographic
assessments. For the clinical evaluation, the functional
movements of the operated limb, without pain, at the end
of the treatment, were measured, and scores ranging from 0
to 3 were given as follows:
score 0: absence of movement of the operated arch or
limb,
score 1: increased limitation of movements,
score 2: same range of movement compared to the
preoperative analysis, and
score 3: normal range of motion of the operated arch
or limb.
For the radiographic analysis, the presence or absence
of integration and the number of surgical procedures
performed until the ﬁnal outcome were considered. The
following scores were given:
score 0: no integration of the bioceramics, indepen-
dent of the number of surgical procedures;
score 1: more than one surgical procedure was
performed in order to observe the bioceramics
integration (and bone formation);
score 2: the bioceramics were integrated and the
patient healed after the ﬁrst surgical procedure.
The ﬁnal results represent the combination of both
parameters, clinical + radiographic scores: 0 to 2 (poor
results), 3 (moderate results), 4 (good results), and 5
(excellent results).
3. Results
The XRD diﬀraction analysis demonstrated the HA/ß-TCP
ratio of the BCP (Figure 1), and the SEM images showed
the presence of micro- and macroporosities in the three
presentation forms of the bioceramics used in this study
(Figure 2).
Of the 67 procedures performed, ﬁve were classiﬁed as
excellentresults(combinedscoreof5),ﬁftysevenprocedures
were classiﬁed as good (combined score of 4), and ﬁve were
classiﬁed as moderate (combined score of 3).
The defects were classiﬁed according to the etiology of
the bone loss, that is, orthopedic or traumatic defects, and
the morphology of the bone defect, that is, segmental (also
called gap defects), or cavitary defects, such as cystic lesions.
In the group classiﬁed according to the etiology of the
defects, thirty two patients underwent thirty three proce-
dures for bone reconstruction with BCP. These patients had
orthopedic bone defects associated with hip or knee prosthe-
sis placement or revisions, osteotomies, and arthrodesis. In
this group, complete integration of the BCP after the ﬁrst
surgical procedure was observed and patients experienced
improved or the same range of motion of the operated limb
or arch without pain. Thus, thirty procedures were classiﬁed
asgoodresults(score4)andthreehadexcellentresults(score
5) (Table 2).
Thirty four patients underwent 34 surgical procedures
to treat traumatic defects. Two of them had excellent ﬁnal
results (score 5), twenty seven had good ﬁnal results (score
4), and ﬁve were classiﬁed as moderate results (score 3).
Four out of the ﬁve moderate results required an additional
surgerytoachievemaximumboneformationintheoperated
site, and one patient had an increased limitation of the limb
movements after the treatment (Table 2).
Regardingthemorphologyofthebonedefect,24patients
with segmental defects underwent 25 procedures, and 42
patients with cavitary bone defects required 42 procedures.
Results of the BCP in repairing cavitary bone defects showed4 International Journal of Biomaterials
Table 2: Final results according to the etiology of the bone defects. The number of patients and procedures and the ﬁnal scores given to
patients with orthopaedic and traumatic defects are described. All procedures performed in orthopaedic defects presented good or excellent
results. Defects caused by trauma are more suitable to show moderate results.
Etiology of the
defect
Number of
patients
Total number
of procedures
Number of
procedures with
excellent results
(score 5)
Number of
procedures with
good results
(score 4)
Number of
procedures with
moderate results
(score 3)
Orthopedic
defects 32 33 3 30 0
Traumatic
defects 34 34 2 27 5
Total 66 67 5 57 5
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Figure 1:X-Raydiﬀractionofbioceramics.ThisanalysisshowsthecrystallinephasesoftheBCPandtheHA/ß-TCPratiowhichcorresponds
to 65%/35%, respectively.
Table 3: Final results according to the morphology of the bone defects. According to the morphology, most of the defects were classiﬁed
as cavitary bone loss and presented good results. Moderate results were observed mainly in segmental defects equal or bigger than 3cm in
length.
Morphology of
the defect
Number of
patients
Total number
of procedures
Lengths of
the defects
Number of
procedures with
excellent results
(score 5)
Number of
procedures with
good results
(score 4)
Number of
procedures with
moderate results
(score 3)
Segmental defects 24 25 <3cm= 19
≥3cm= 6
<3cm= 3
≥3cm= 0
<3cm= 15
≥3cm= 2
<3cm= 1
≥3cm= 4
Cavitary defects 42 42 Not
measured 24 00
Total 66 67 — 5 57 5International Journal of Biomaterials 5
Granules 20–40 mesh Granules 40–60 mesh Preshaped wedges
SE SE SE WD 10mm 10kV x500 100μm WD 10mm 10kV x500 100μm WD 10mm 10kV x500 100μm
(a)
Granules 20–40 mesh Granules 40–60 mesh Preshaped wedges
SE SE SE WD 10mm 10kV 10 μm WD 10kV 10μm WD 10kV 5mm 5mm 10μm x4k 5 xk 5 xk
(b)
Figure 2: SEM images showing the physical structures of the granules 20–40mesh, 40–60mesh and preshaped wedge. The macroporosities
(a) and microporosities (b) can be observed in all the samples.
good results for 40 procedures (score 4) and excellent results
for 2 procedures (score 5) (Table 3).
Nineteen procedures were performed in segmental bone
defects smaller than 3cm in length and 6 procedures were
performed in 3cm defects or larger (Table 4).
Within the segmental defects that were smaller than 3cm
in length, three of them presented excellent results (score
5), 15 were classiﬁed as good results (score 4) and one had
a moderate result (score 3). It is important to highlight,
however, that in this particular case, the moderate result
w a sn o td u et op r o b l e m sw i t ht h eb i o c e r a m i c sb u td u et o
the shortening of the limb at the end of the treatment.
As a consequence, the patient required a second surgical
procedure, where the osteotomy for the limb lengthening
was performed throughout the area that had been previously
reconstructed with the bioceramics (Figure 3).
Of the 6 patients with bone defects equal or bigger
than 3cm in length, only two of them showed healing
after the ﬁrst surgery. One of them, however, received score
3 (moderate result) instead of 4 (good results) due to
increased limitation of the knee movements. Three patients
required a second surgical intervention, and one patient,
with a defect of 11cm in length, required a third procedure.
Consequently, 2 procedures were classiﬁed as good (score 4)
and 4 procedures, as moderate (score 3).
Only three patients out of 66 received BCP combined
with autologous bone grafts in the ﬁrst surgical intervention.
These results were diﬀerent for each of these 3. One patient
had a cavitary bone defect that healed well, receiving score
5, one patient, with a segmental bone defect of 4cm in
length, had a nonunion and required an additional surgical
procedure using only BCP without autografts and received
score 3, and one patient with 11cm length segmental defect
required an additional surgery, receiving score 3 at the end of
the treatment (Table 4).
None of the patients experienced poor results, that is, no
integration of the bioceramics (Table 5) that could be either
associated or not to an increased limitation or absence of
movements.
4. Discussion
This study evaluated the eﬃcacy of a biphasic calcium
phosphate (BCP) bioceramics in the reconstruction of
bone defects caused by trauma or associated with elective
procedures such as prosthesis placement and revisions,
arthrodesis, and osteotomies (called orthopedic defects) as
well as in the reconstruction of cavitary and segmental bone
defects.
As c a l eo fd i ﬀerent scores was used in order to measure
the clinical and radiographic outcomes. Similar scoring scale
has been used in a previous study [21]. We have shown
that the BCP was successful in regenerating bone in all the
cavitary and in segmental bone defects where the gaps were
smaller than 3 centimetres in length. Most of these defects
were also classiﬁed as orthopaedic defects. Segmental defects
equal or larger than 3 centimetres in length, which were
mostly caused by trauma, required special attention and
eventually needed an additional surgical procedure to heal.
In some of these patients, as the healing period was longer
than for those with smaller defects, the substitution of the
pins and nails used for ﬁxation was required due to their6 International Journal of Biomaterials
A
A
Figure 3: Bone lengthening in an area previously reconstructed with BCP. X-Ray and CT images of a tibia showing the zone reconstructed
with BCP (A) and the new bone formed after osteotomy and bone lengthening, which was performed due to the shortening of the limb.
SE 10kV WD 5mm 50μm xk 1
Figure 4 :H u m a nm e s e n c h y m a ls t e mc e l l so nt h es u r f a c eo fa
granule (40–60mesh). SEM image shows stem cells spreading on
the BCP surface and forming layers over the apertures of porous,
after 7 days of culture.
movements and instability over time. None of the patients
presented acute inﬂammatory reactions or infections. One
of the factors that has been described as eliciting response
of cells such as monocytes, which are among the ﬁrst
cells to contact the implant surface and to colonize the
inﬂammatory site, is the ratio between the surface area of
cells and the surface area of the biomaterial [22, 23]. The
ratiorelatedtothesurfaceareaofcell/surfaceareaofmaterial
equivalent to one has been shown to elicit the highest level
of inﬂammatory cytokine production [22, 23]. The granule
sizes used in these clinical cases are much bigger than all
cells, as shown by the SEM analysis (Figure 4). The chemical
(a) (b)
Figure 5: Reconstruction of a femoral bone defect with BCP. X-Ray
images of a femur before (a) and after (b) reconstruction with the
BCP and stabilized with internal ﬁxation system, after trauma.
composition, topography, wettability, and surface energy of
the biomaterial are other factors that will inﬂuence cell
response [24, 25].
Our radiographic analysis showed a higher radiopacity
at the implant site even in the long-term evaluation (Figures
3, 5,a n d6). This is in agreement with the study reported
by Rouvillain et al. [26] that showed the same imageInternational Journal of Biomaterials 7
(a) (b) (c)
Figure 6: A tibial bone defect reconstructed with BCP. X-Ray image of a tibial fracture (a) with the lateral (b) and anterior view (c) after 2
years of reconstruction using the BCP.
Table 4: Lengths of the segmental bone defects. Nineteen proce-
dureswereperformedindefectssmallerthan3cminlengthandsix,
in defects equal or larger than 3cm. The ﬁnal scores (combination
of clinical and radiographic analysis) are described. One patient
received bilateral intervention. The majority of good and excellent
results (scores 4 and 5) were observed in patients with defects equal
or smaller than 3cm in length.
Procedure ID Length of the defect Bone aﬀected Final score
1 11 Femur 3
32 F e m u r 4
13 3 Femur 3
14 1.5 Femur 4
17 1 Tibia 4
22 1 Clavicle 5
26 3.5 Femur 4
27 0.5 Clavicle 5
35 2.5 Forearm 4
36 1 Forearm 4
37 0.5 Femur 4
40 1 Femur 4
41 5 Femur 3
43 1 Femur 4
45 0.5 Clavicle 5
46 1.5 Humerus 4
47 2 Tibia 3
48 4 Tibia 3
49 1.5 Radius 4
50 2.5 Humerus 4
51 3 Humerus 4
54 2 Femur 4
55 2.5 Humerus 4
62 2 Femur 4
63 1 Femur 4
characteristic even after 18 months of the implantation of
BCP(60%HA/40% β-TCP)wedges inhightibial valgisation
Table 5: Results of the radiographic analysis according to the
etiology of the bone defects. Most of the patients received score 2,
corresponding to the integration of the bioceramics after the ﬁrst
surgical procedure.
Etiology of the
bone defects
Number of procedures according to the
radiographic scores
Score 0 Score 1 Score 2
Traumatic defects — 4 30
Orthopedic defects — — 33
osteotomies. These authors gave evidences of a resorption
rate corresponding to more than 60% of the bioceramics
after 2 years and demonstrated that the high radiopacity was
due to the greater mineral concentration and the composite
formed by the new bone tissue and the residual granules and
not due to the nonresorption of the biomaterial [26]. Our
good results are in agreement with those reported by others
[27].
Since the ﬁrst successful clinical application of com-
mercial calcium phosphate bioceramics in the early 1970s,
modiﬁcations on their properties gave rise to alternatives
with improved biological and mechanical properties [7, 9,
10, 17, 28–30].
The BCP used in this study consisted of 65% of HA
and 35% of β-TCP and belongs to the third generation of
biomaterials, namely, those having appropriate micro- and
macroporosities, good mechanical properties, and promot-
ing not only bone substitution but also bone regeneration
[9]. An animal study showed that such bioceramics, in the
granular form (40–60 mesh) promoted a bone mass gain up
to 4-fold the initial volume used [20].
The nature, timing and progression of the bone regen-
eration, was shown to be inﬂuenced not only by the bone
physiology, biomechanical properties at the site of the lesion,
age, and intrinsic conditions of the patient but also by the
chemical composition and physical structure of bone graft
substitute, which will directly inﬂuence the migration and
proliferation of the host cells [7, 10, 15, 18, 19, 31–33].8 International Journal of Biomaterials
F o rab i o m a t e r i a lt of u n c t i o na sag o o ds c a ﬀold, it must
not be prematurely resorbed before the new bone formation
occurs. For this reason, highly soluble compounds, such
as calcium sulphate, calcium carbonate, dicalcium phos-
phatedihydrate,octacalciumphosphate,andbeta-tricalcium
phosphate alone, may not be suitable materials for the
reconstruction of major bone defects in humans, even if in
vitro cell response to these calcium phosphate materials is
positive. Bioceramics with rapid resorption or dissolution
rate promotes an important change of the local pH due
to the high levels of calcium ions released, leading to a
mild inﬂammatory process and/or to a ﬁbrous encapsulation
of the material [31, 34] resulting in an unsuccessful bone
regeneration.
Thus, in the time-dependent process of bone formation,
the degradation rate is a key point for the clinical success,
mainly when larger defects are being treated. Indubitably the
use of BCP with diﬀerent ratios of low soluble component
(HA) and a highly soluble phase (β-TCP) is an option to
tailor the degradation kinetics of calcium bioceramics from
a few weeks to a few years [5, 7, 10, 11, 15].
Some calcium phosphate (CaP) bioceramics with dif-
ferent physical structures (including the size and density
of porosity) and chemical composition have been used
alone or mixed with adjuvants of bone healing (e.g., ﬁbrin
sealant,platelet-richplasmaandstemcells)inseveralclinical
situations with good results [35–43]. However, in most of
these cases, the bioceramics were applied in relatively small
bone defects.
Diﬀerent results were obtained from the 3 patients
who were treated with a combination of BCP/autografts.
Considering that this number of patients is very low and
the results are not consistent, no conclusion can be made
about the possible beneﬁts of combining autografts with
BCP. Further studies still must be performed in order to
collect evidences that support the real advantages of such
strategy.
Anothercrucialpointthatmustbetakenintoaccountfor
a successful clinical treatment is the correct preparation of
the surgical site. All the surgical technique principles that are
indicated for the autologous bone grafting must be applied
for the bioceramics implantation. Indeed, avoiding infected
areas, eliminating all the granular tissues and ﬁbrosis at the
surgical site, and impacting the biomaterial where healthy
and bloody bone extremities are observed are crucial steps.
5. Conclusions
This study showed clinical evidences of the eﬃcacy of the
micro- and macroporous biphasic calcium phosphate (BCP)
bioceramicswith65HA/35β-TCPratio,inthereconstruction
of not only small but also large bone defects in humans.
Results from this study suggest that such material can
be used in load-bearing areas and represents a safe and
predictablealternativeforautograftsandallografts.Incaseof
segmental bone defects equal or larger than 3cm in length,
the association of BCP scaﬀolds, such as the ones used in
this study, with bioactive molecules or stem cells may be
considered.
Knowledge of the bioceramics properties and application
of appropriate surgical techniques are critical aspects for
good clinical outcomes.
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